US Patent Issued to Bristol-Myers Squibb on March 31 for "Cancer immunotherapy by disrupting PD-1/PD-L1 signaling" (Pennsylvania, Maryland, New Jersey, Massachusetts Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,154, issued on March 31, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Cancer immunotherapy by disrupting PD-1/PD-L1 signaling" was invented by John P. Cogswell (Yardley, Pa.), Stacie M. Goldberg (Potomac, Md.), Ashok K Gupta (Clarksburg, Md.), Maria Jure-Kunkel (Plainsboro, N.J.), Xi-Tao Wang (Wellesley, Mass.) and Jon M. Wigginton (Collegeville, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/P...